Ucb UCB.BE | BRUSSELS Exch | Medical-Diversified | MktCap €38.87B Sales €6.85B | Shares 195M Float 99M

3225599999
EPS Rank 77

ucb.com

Brussels, BELGIUM Inc 1925

MGMT owns --

UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. MORE

ANNUAL - DEC END	2016	2017	2018	2019	2020	2021	2022	2023	2024
EPS EUR	2.88	3.99	4.20	4.23	3.87	5.60	2.20	1.81	5.61
CASH FLOW/SHR EUR	1.85	4.64	5.44	4.40	5.20	7.67	5.36	3.16	5.56
PRETAX MARGIN %	18%	22%	22%	20%	16%	21%	9%	8%	19%
RETURN ON EQUITY %	10%	13%	13%	12%	10%	14%	5%	4%	11%
SALES % CHANGE	7%	9%	2%	6%	9%	8%	-5%	-5%	17%
SALES (MIL) EUR	4,147	4,530	4,632	4,913	5,347	5,777	5,517	5,252	6,152
WEEKLY	**Jul 4**	**Jul 11**	**Jul 18**	**Jul 25**	**Aug 1**	**Aug 8**	**Aug 15**	**Aug 22**	**Aug 29**
DATAGRAPH RATING	55	59	66	64	66	64	69	68	70
AVG DAILY VOL (000)	250	235	221	216	227	211	203	203	197
UP DOWN VOLUME	1.4	1.3	1.6	1.6	1.8	1.5	1.4	1.5	1.7
ACCUM/DIST RATING	15	21	24	31	34	33	31	36	29
RELATIVE STRENGTH	59	70	77	64	63	64	80	78	82
GROUP RANK	42	43	41	39	30	29	23	22	19

2025 Estimate	2026 Estimate
7.22 29%	9.83 36%
Earnings Growth Rate	**Sales Growth Rate**
2023-25 25% (69 Stability)	5%
2021-25 -7% (65 Stability)	3%
COMP RATING 98	SMR RATING A
INV T/O 1.7x 38	

DEBT %	2022-24	29%	33%	30%
TAX RATE	2022-24	18%	22%	8%
BACKLOG	2022-24	--	--	--
R & D	28.90%	BK VAL 3.79x '24		
DIV EUR	0.97 (0.5%)	DIV GR RT. 2% (0)		
BETA	1.55(44.00)	ALPHA 0.01 (0.00)		
2024 EMPLOYEES 9,378 (3%)				

Exclusive Long Idea

Developed Long +4.94% in 4.1 WKS

OH -3% LOG (Fixed) PRICE

The stock broke out of a stage-one consolidation base with a pivot of €198.95. Support at its rising 21-DMA (€193.01)

Good Up/Down Volume ratio, Acc/Dist Rating, and Group Rank

Strong Composite Rating of 98 and SMR Rating of A. Double-digit EPS growth estimates for 2025 and 2026

RS line is trending upward, with good money flows





FINANCIALS	20	Dec 20	Mar 21	Jun 21	Sep 21	Dec 21	Mar 22	Jun 22	Sep 22	Dec 22	Mar 23	Jun 23	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Mar 25	Jun 25	Sep
EPS (EUR)		1.95		3.02		2.58		2.10		0.10		1.64		0.17		1.10		4.51		2.50	
EPS % CHANGE		-3%		+57%		+32%		-30%		-96%		-22%		+70%		-33%		+2,553%		+127%	
SALES (MIL EUR)		2,739.0		2,778.0		2,999.0		2,925.0		2,592.0		2,589.0		2,663.0		2,791.0		3,361.0		3,487.0	
SALES % CHANGE		+6%		+7%		+9%		+5%		-14%		-11%		+3%		+8%		+26%		+25%	
EPS % SURPRISE		+28.0%		+11.5%		+17.2%		-16.4%		+61.6%		+55.9%		+16.4%		+18.6%		+10.6%		+6.8%	
FUNDS	423	1,397	1,368	1,378	1,391	1,391	1,469	1,580	1,414	1,402	1,389	1,387	1,432	1,465	1,474	1,592	1,699	1,829	1,824	1,833	
SHARES HELD BY FUNDS	4M	54M	53M	55M	55M	57M	56M	55M	54M	54M	53M	53M	54M	53M	58M	61M	62M	62M	60M	58M	

P/E	29
2025 Est.:	27.7
2026 Est.:	20.3
5-yr High:	111
5-yr Low:	15
vs Ind. Avg:	1.2x

PANARAY® 2025 WILLIAM O'NEIL + CO. INC.